|

Extended Dosing Interval - B Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • National University Hospital, Singapore1

Indications

  • Liver Disease1
  • GastroEsophageal Cancer1
  • Gastric Adenocarcinoma1
  • Oesophageal Cancer1
  • Carcinoma, Hepatocellular1

Other1 trial

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.